SAN DIEGO, Nov. 12, 2020 /PRNewswire/ -- Evofem
Biosciences, Inc., (NASDAQ: EVFM) today announced it will present
at the Stifel Virtual Healthcare Conference on Wednesday November 18, 2020 at 4:00 p.m. ET.
To access the live and archived webcast of this fireside chat,
visit the Investors section of the Evofem Biosciences website
at www.evofem.com, and select the Events and
Presentations tab.
About Evofem Biosciences
Evofem Biosciences, Inc.,
(NASDAQ: EVFM) is a commercial-stage biopharmaceutical company
committed to developing and commercializing innovative products to
address unmet needs in women's sexual and reproductive health,
including hormone-free, woman-controlled contraception and
protection from certain sexually transmitted infections (STIs). The
Company's first commercial product, Phexxi™ (lactic acid, citric
acid and potassium bitartrate), is the first and only hormone-free,
prescription vaginal gel approved in the United
States for the prevention of pregnancy. The Company is
evaluating EVO100 in a Phase 3 clinical
trial, 'EVOGUARD,' for the prevention of urogenital
Chlamydia trachomatis and Neisseria
gonorrhoeae infection in women. For more information,
please visit www.evofem.com.
Phexxi™ is a trademark of Evofem Biosciences, Inc.
Investor Relations Contact
Amy
Raskopf
Evofem Biosciences, Inc.
araskopf@evofem.com
Mobile: (917) 673-5775
Media Contact
Ellen
Thomas
Evofem Biosciences, Inc.
ethomas@evofem.com
Mobile: (718) 490-3248
View original content to download
multimedia:http://www.prnewswire.com/news-releases/evofem-biosciences-to-present-at-stifel-virtual-healthcare-conference-301171760.html
SOURCE Evofem Biosciences, Inc.